Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 90, Issue 10, Pages 1161-1171Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00109-012-0888-x
Keywords
Cancer; 2-Hydroxyglutarate; Isocitrate dehydrogenase; Nuclear magnetic resonance; Biomarker
Funding
- NIH [R01 CA86335, CA116804, R21AG032104-01A1, P50CA128301-020003, P30 CA138292]
- NINDS [2T32NS007480-11]
- Winship Cancer Institute
- Atlanta Clinical & Translational Science Instite (ACTSI) [UL1RR025008]
- Brain Tumor Funders Collaborative
- Georgia Cancer Coalition
Ask authors/readers for more resources
Somatic mutations in isocitrate dehydrogenase (IDH)1 and 2 have been identified in a subset of gliomas, rendering these tumors with elevated levels of oncometabolite, D-2-hydroxyglutarate (2HG). Herein, we report that 2HG can be precisely detected by magnetic resonance (MR) in human glioma specimens and used as a reliable biomarker to identify this subset of tumors. Specifically, we developed a two-dimensional correlation spectroscopy resonance method to reveal the distinctive cross-peak pattern of 2HG in the complex metabolite nuclear MR spectra of brain tumor tissues. This study demonstrates the feasibility, specificity, and selectivity of using MR detection and quantification of 2HG for the diagnosis and classification of IDH1/2 mutation-positive brain tumors. It further opens up the possibility of developing analogous non-invasive MR-based imaging and spectroscopy studies directly in humans in the neuro-oncology clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available